Previous 10 | Next 10 |
Aridis Pharmaceuticals (NASDAQ: ARDS ): Q4 GAAP EPS of -$0.63 beats by $0.17 . More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN JOSE, Calif. , April 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate resul...
New York City, NY:March 26, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Acinetobacter Infections Treatment Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the r...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SAN JOSE, Calif. , March 6, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the postponement of its...
Alector (NASDAQ: ALEC ) initiated with Buy rating and $44 (52% upside) price target at Stifel. More news on: Alector, Inc., Aridis Pharmaceuticals, Inc., BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
SAN JOSE, Calif. , Feb. 18, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it will host an In...
SAN JOSE, Calif. , Jan. 28, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company") presented a comprehensive profile of its APEX ™ platform technology at the antibody and cell engineering conference 19 th Annual PepTalk: The Protein Science Week on ...
Aridis Pharmaceuticals (NASDAQ: ARDS ) appoints Michael A. Nazak as its Chief Financial Officer effective January 1, 2020. More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
SAN JOSE, Calif. , Jan. 2, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infection...
News, Short Squeeze, Breakout and More Instantly...
Aridis Pharmaceuticals Inc. Company Name:
ARDS Stock Symbol:
NASDAQ Market:
Aridis Pharmaceuticals Inc. Website:
Biomerieux (BMXMF) is expected to report for Q1 2024 Conn's Inc. (CONN) is expected to report $-0.65 for Q1 2025 Cognetivity Neurosciences Ltd (CGNSF) is expected to report for quarter end 2024-04-30 Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q1 2024 China Jo-Jo ...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Commercial Metals Company (CMC) is expected to report $1 for Q3 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 GMS Inc. (GMS) is expected to report $2.04 for Q4 2024 China Jo-Jo Drugstores Inc. (CJJD) is expected to report for Q4 2024 Eiger BioPharmaceuticals Inc. (EIGR...